J Vaňásek - Concepedia

Author

J Vaňásek

University Hospital Hradec Králové ORCID

Also Known As

J VANASEK, J Vanasek, J Vanásek, J Vanåsek, J Vaňásek, J. VANASEK, J. Vanasek, J. Vanásek, J. Vaňásek, JAROSLAV VANASEK

147

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

University Hospital Hradec Králové Charles University Pardubice Region University of Pardubice University Hospital Olomouc

About

J Vaňásek is an author at University Hospital Hradec Králové specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	789
2	Health Sciences	6	6	696
3	Cell Biology	3	3	37
4	Immunology	3	3	37
5	Engineering	1	1	20

J Vaňásek

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Platelet Transfusion Therapy Michael J. Blaha, Joe Maly, J Vaňásek, JAMA	1987	194
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial Renato D. Lópes, Celestia S. Higano, Susan F. Slovin, Circulation	2021	141
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang, Annals of Oncology Antifibrotic TherapyFortis-m TrialMedicineMetronomic TherapyPharmacology	2013	55
Dose Escalation in Prostate Radiotherapy up to 82 Gy Using Simultaneous Integrated Boost Martin Doležel, Karel Odrážka, Miloslava Vaculíková, Strahlentherapie und Onkologie Adaptive RadiotherapyRadiation MedicineRadiation TherapyDose EscalationMedicine	2010	41
Time course of late rectal toxicity after radiation therapy for prostate cancer Karel Odrážka, Martin Doležel, J Vaňásek, Prostate Cancer and Prostatic Diseases UrologyRadiation MedicineSurgical OncologyRadiation TherapyMedicine	2009	33
Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer Martin Doležel, Karel Odrážka, Milan Zouhar, Strahlentherapie und Onkologie Radiation MedicineMedicineRadiation Therapy PlanningProstatic DiseaseComparative Planning	2015	32
Late toxicity after conformal and intensity‐modulated radiation therapy for prostate cancer: Impact of previous surgery for benign prostatic hyperplasia Karel Odrážka, Martin Doležel, J Vaňásek, International Journal of Urology	2010	27
MRI-based Preplanning Using CT and MRI Data Fusion in Patients With Cervical Cancer Treated With 3D-based Brachytherapy: Feasibility and Accuracy Study Martin Doležel, Karel Odrážka, Ján Žižka, International Journal of Radiation OncologyBiologyPhysics Computed TomographyMri Data FusionEngineeringCervical CancerMedical Imaging	2012	20

Page 1